Jenburkt Pharmaceuticals (524731) Q2 26/27 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 26/27 earnings summary
3 Nov, 2026Executive summary
Q2 FY27 revenue from operations was ₹4,831.82 lakh and PAT was ₹1,020.94 lakh; H1 revenue was ₹8,383.02 lakh and PAT was ₹1,609.50 lakh.
H1 revenue exceeded ₹8,108.44 lakh in the prior-year period, while H1 PAT was below ₹1,795.52 lakh.
Financial highlights
Q2 total income was ₹5,057.08 lakh; profit before tax was ₹1,433.95 lakh.
H1 total income was ₹8,759.60 lakh and profit before tax was ₹2,110.86 lakh, versus ₹8,522.05 lakh and ₹2,451.40 lakh in H1 FY26.
Q2 EPS was ₹23.13; H1 EPS was ₹36.47, compared with ₹40.68 in H1 FY26.
Segment performance
Operations are exclusively in the pharmaceuticals business segment; segment-wise reporting is not applicable.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Jenburkt Pharmaceuticals
- Q1 FY27 profit after tax declined to ₹588.56 lakhs, with EPS at ₹13.34.524731
Q1 26/27 - Revenue and profit rose, dividend declared, and audit opinion unmodified for FY 2025-26.524731Q4 25/26
- Q3 FY26 saw higher revenue but lower profit after tax and EPS, with added labour cost provisions.524731Q3 25/26
- Revenue and net profit rose year-over-year, with EPS at ₹23.03 and strong cash flow.524731Q2 25/26
- Revenue and profit after tax rose year-over-year, with EPS reaching ₹17.66.524731Q1 25/26
- Strong revenue and profit growth reported for Q2 FY25, with higher EPS and cash flow.524731Q2 24/25
- Q1 FY25 saw higher revenue, profit, and EPS, with continued focus on pharmaceuticals.524731Q1 24/25
- Q3 FY25 saw higher revenue, profit, and EPS, with clean auditor review and pharma focus.524731Q3 24/25
- FY25 net profit rose 23% to ₹3,206 lakh; ₹18/share dividend declared.524731Q4 24/25